C5 Antibody (557): sc-52635

C5 Antibody (557) is a mouse monoclonal IgG2b antibody that detects C5 in human samples through applications such as western blotting (WB) and immunoprecipitation (IP). C5 is a crucial component of the complement system, playing a pivotal role in immune response by being cleaved into C5a and C5b during complement activation. C5a acts as a potent anaphylatoxin, essential for mediating inflammatory responses and recruiting immune cells to sites of infection or injury. This process is vital for eliminating pathogens and initiating tissue repair. C5a exerts effects by binding to specific G protein-coupled receptors on myeloid leukocytes, leading to a cascade of proinflammatory events, including cellular degranulation and cytokine release. Proper functioning of C5 and derivatives is critical, as dysregulation can contribute to various pathophysiological conditions, including asthma and bacterial meningitis. C5 precursor undergoes significant post-translational modifications, including cleavage by C5 convertase, essential for generating active anaphylatoxin C5a. Understanding C5 and interactions within the complement system is crucial for developing therapeutic strategies targeting inflammatory diseases. Anti-C5 antibody (557) provides a reliable tool for researchers investigating complex mechanisms of immune response and complement proteins in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

C5 Antibody (557) References:

1. Complement component C5 is not involved in scrapie pathogenesis.  |  Mabbott, NA. and Bruce, ME. 2004. Immunobiology. 209: 545-9. PMID: 15568618
2. The complement component 5 gene and age-related macular degeneration.  |  Baas, DC., et al. 2010. Ophthalmology. 117: 500-11. PMID: 20022638
3. Inhibiting the C5-C5a receptor axis.  |  Woodruff, TM., et al. 2011. Mol Immunol. 48: 1631-42. PMID: 21549429
4. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis.  |  Woehrl, B., et al. 2011. J Clin Invest. 121: 3943-53. PMID: 21926466
5. A small-molecule inhibitor of C5 complement protein.  |  Jendza, K., et al. 2019. Nat Chem Biol. 15: 666-668. PMID: 31209353
6. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria.  |  Fattizzo, B. and Kulasekararaj, AG. 2020. BioDrugs. 34: 149-158. PMID: 31916226
7. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.  |  Badri, P., et al. 2021. Clin Pharmacokinet. 60: 365-378. PMID: 33047216
8. Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease.  |  Ozen, A., et al. 2021. Nat Immunol. 22: 128-139. PMID: 33398182
9. Dual inhibition of complement component 5 and leukotriene B4 by topical rVA576 in atopic keratoconjunctivis: TRACKER phase 1 clinical trial results.  |  Sánchez-Tabernero, S., et al. 2021. Orphanet J Rare Dis. 16: 270. PMID: 34116700
10. The activation of human complement component C5 by a fluid phase C5 convertase.  |  DiScipio, RG., et al. 1983. J Biol Chem. 258: 10629-36. PMID: 6554279

The preferred C5b-9 antibody is C5b-9 Antibody (aE11): sc-58935.